Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 673 to 675 of 675 entries
Sorted by: Best Match Show Resources per page
Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study.

Drugs - real world outcomes

Tsukada N, Nishikori M, Goto H, Kanamori R, Nishina S, Seto T, Iida S.
PMID: 34455570
Drugs Real World Outcomes. 2021 Aug 29; doi: 10.1007/s40801-021-00276-1. Epub 2021 Aug 29.

BACKGROUND: Plerixafor was approved in Japan in 2016 for peripheral blood stem cell (PBSC) mobilization in autologous stem cell transplantation (A-SCT).OBJECTIVE: Our objective was to evaluate the safety and effectiveness of plerixafor in Japanese patients undergoing A-SCT for various...

Cite
Tsukada N, Nishikori M, Goto H, et al. Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs Real World Outcomes. 2021;doi: 10.1007/s40801-021-00276-1.
Tsukada, N., Nishikori, M., Goto, H., Kanamori, R., Nishina, S., Seto, T., & Iida, S. (2021). Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs - real world outcomes, . https://doi.org/10.1007/s40801-021-00276-1
Tsukada, Nobuhiro, et al. "Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study." Drugs - real world outcomes vol. (2021). doi: https://doi.org/10.1007/s40801-021-00276-1
Tsukada N, Nishikori M, Goto H, Kanamori R, Nishina S, Seto T, Iida S. Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs Real World Outcomes. 2021 Aug 29; doi: 10.1007/s40801-021-00276-1. Epub 2021 Aug 29. PMID: 34455570.
Copy Download .nbib Format: NLM
Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer.

Molecular and clinical oncology

Nagata T, Kanamori M, Sekine S, Arai M, Moriyama M, Fujii T.
PMID: 33796292
Mol Clin Oncol. 2021 May;14(5):103. doi: 10.3892/mco.2021.2265. Epub 2021 Mar 17.

Modulated electro-hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance-matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their...

Cite
Nagata T, Kanamori M, Sekine S, et al. Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer. Mol Clin Oncol. 2021;14(5):103doi: 10.3892/mco.2021.2265.
Nagata, T., Kanamori, M., Sekine, S., Arai, M., Moriyama, M., & Fujii, T. (2021). Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer. Molecular and clinical oncology, 14(5), 103. https://doi.org/10.3892/mco.2021.2265
Nagata, Takuya, et al. "Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer." Molecular and clinical oncology vol. 14,5 (2021): 103. doi: https://doi.org/10.3892/mco.2021.2265
Nagata T, Kanamori M, Sekine S, Arai M, Moriyama M, Fujii T. Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer. Mol Clin Oncol. 2021 May;14(5):103. doi: 10.3892/mco.2021.2265. Epub 2021 Mar 17. PMID: 33796292; PMCID: PMC8010507.
Copy Download .nbib Format: NLM
Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections.

Internal medicine (Tokyo, Japan)

Matsuba I, Takuma T, Hatori N, Takai M, Watanabe Y, Takada N, Kishi S, Matsuzawa Y, Nishikawa T, Kunishima T, Degawa H, Nishikawa M, Ono Y, Kanamori A.
PMID: 34744105
Intern Med. 2022 Jan 15;61(2):159-165. doi: 10.2169/internalmedicine.8019-21. Epub 2021 Nov 06.

Objective To examine the continuation of antibody prevalence and background factors in antibody-positive subjects after asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods A study was carried out to investigate the SARS-CoV-2 antibody (IgG) prevalence. SARS-CoV-2...

Cite
Matsuba I, Takuma T, Hatori N, et al. Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Intern Med. 2021;61(2):159-165doi: 10.2169/internalmedicine.8019-21.
Matsuba, I., Takuma, T., Hatori, N., Takai, M., Watanabe, Y., Takada, N., Kishi, S., Matsuzawa, Y., Nishikawa, T., Kunishima, T., Degawa, H., Nishikawa, M., Ono, Y., & Kanamori, A. (2022). Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Internal medicine (Tokyo, Japan), 61(2), 159-165. https://doi.org/10.2169/internalmedicine.8019-21
Matsuba, Ikuro, et al. "Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections." Internal medicine (Tokyo, Japan) vol. 61,2 (2022): 159-165. doi: https://doi.org/10.2169/internalmedicine.8019-21
Matsuba I, Takuma T, Hatori N, Takai M, Watanabe Y, Takada N, Kishi S, Matsuzawa Y, Nishikawa T, Kunishima T, Degawa H, Nishikawa M, Ono Y, Kanamori A. Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Intern Med. 2022 Jan 15;61(2):159-165. doi: 10.2169/internalmedicine.8019-21. Epub 2021 Nov 06. PMID: 34744105.
Copy Download .nbib Format: NLM
Showing 673 to 675 of 675 entries